Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 42
- Registration Number
- NCT02316340
- Locations
- 🇺🇸
Cancer Therapy and Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2018-02-22
- Target Recruit Count
- 12
- Registration Number
- NCT02124083
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02114502
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
- Conditions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2018-09-14
- Target Recruit Count
- 7
- Registration Number
- NCT02108002
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: Anti-Thymocyte GlobulinDrug: BusulfanDrug: ClofarabineDrug: Fludarabine PhosphateProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Vorinostat
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT02083250
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT02042989
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- Conditions
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2022-06-08
- Target Recruit Count
- 114
- Registration Number
- NCT02035137
- Locations
- 🇺🇸
Children Hospital of Colorado, Aurora, Colorado, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT01983969
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Melissa Burgess, MD
- Target Recruit Count
- 37
- Registration Number
- NCT01879085
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Registration Number
- NCT01838187
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.